Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

Cancer

Volumn 122, Issue 14, 2016, Pages 2178-2185

  Kantarjian, Hagop M ^a   Stein, Anthony S ^b   Bargou, Ralf C ^c   Grande Garcia, Carlos ^d   Larson, Richard A ^e   Stelljes, Matthias ^f   Gökbuget, Nicola ^g   Zugmaier, Gerhard ^h   Benjamin, Jonathan E ⁱ   Zhang, Alicia ⁱ   Jia, Catherine ⁱ   Topp, Max S ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h Amgen Research GmbH   (Germany)

ⁱ AMGEN INC   (United States)

Author keywords

acute lymphoblastic leukemia; bispecific antibodies; blinatumomab; elderly; relapsed refractory

Indexed keywords

BLINATUMOMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; METHOTREXATE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; APHASIA; APRAXIA; ARTICLE; ATAXIA; B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; BALANCE DISORDER; BRAIN DISEASE; CANCER PROGNOSIS; COGNITIVE DEFECT; CONFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CONVULSION; CYTOKINE RELEASE SYNDROME; DEVICE INFECTION; DISORIENTATION; DIZZINESS; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT INTERRUPTION; TREMOR;

EID: 84977504252     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30031     Document Type: Article

References (27)

1. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-3197.
2. Marks DI. The challenges of managing older patients with acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2015;35:e343-e351.
3. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463-471.
4. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032-2041.
5. Gökbuget N. How I treat older patients with ALL. Blood. 2013;122:1366-1375.
6. Frey NV, Luger SM. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2015;126:589-596.
7. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944-950.
8. Weiss MA. Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Leukemia. 1997;11(suppl 4):S28-S30.
9. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-977.
10. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134-4140.
11. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66.
12. National Cancer Institute. NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Bethesda, MD: National Cancer Institute; 2014.
13. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72:511-518.
14. Daenen S, van der Holt B, Dekker AW, et al. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia. 2012;26:1726-1729.
15. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
16. Martell MP, Atenafu EG, Minden MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013;163:458-464.
17. Sancho JM, Ribera JM, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007;78:102-110.
18. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863-871.
19. O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113:2097-2101.
20. Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005:131-136.
21. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226-6233.
22. Hahn T, McCarthy PL Jr, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437-2449.
23. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-1833.
24. Marks DI, Wang T, Perez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116:366-374.
25. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439-4443.
26. Kanamori H, Mizuta S, Kako S, et al. Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2013;48:1513-1518.
27. Reshef R, Huffman AP, Gao A, et al. High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2015;33:2392-2398.